Protalix BioTherapeutics Inc. (PLX) Sees Significant Growth in Short Interest

Protalix BioTherapeutics Inc. (NYSE:PLX) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 742,145 shares, a growth of 4.2% from the September 15th total of 712,565 shares. Based on an average daily trading volume, of 58,421 shares, the short-interest ratio is currently 12.7 days. Approximately 0.8% of the company’s stock are short sold.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Protalix BioTherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 27th. Jefferies Group decreased their target price on shares of Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating for the company in a research note on Tuesday, September 6th. Finally, Rodman & Renshaw reissued a “buy” rating on shares of Protalix BioTherapeutics in a research note on Monday, July 11th.

Protalix BioTherapeutics (NYSE:PLX) opened at 0.485 on Wednesday. The company has a market capitalization of $48.38 million and a P/E ratio of 0.958. Protalix BioTherapeutics has a 52 week low of $0.48 and a 52 week high of $1.25. The firm has a 50 day moving average of $0.58 and a 200-day moving average of $0.70.

Protalix BioTherapeutics (NYSE:PLX) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $1.77 million for the quarter, compared to analyst estimates of $1.34 million. During the same quarter last year, the company posted ($0.05) earnings per share. On average, analysts forecast that Protalix BioTherapeutics will post ($0.41) earnings per share for the current year.

5 Day Chart for NYSE:PLX

Receive News & Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.